A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5212-5223

  Passalacqua, Karla D ^a   Satola, Sarah W ^a,b   Crispell, Emily K ^b   Read, Timothy D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CEFOXITIN; CELL SURFACE PROTEIN; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; FIBRINOGENBBINDING PROTEIN; GENOMIC DNA; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; OXACILLIN; PENICILLIN DERIVATIVE; PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2C; RIFAMPICIN; SECOND IMMUNOGLOBULIN BINDING PROTEIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOLYSIS; BACTERIAL CELL WALL; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATION; DNA ISOLATION; GENE MUTATION; INDEL MUTATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REGULATOR GENE; STAPHYLOCOCCUS AUREUS; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VANCOMYCIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DAPTOMYCIN; MUTATION; PHOSPHOPROTEIN PHOSPHATASES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84866335623     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05770-11     Document Type: Article

References (84)

1. Adam HJ, et al. 2010. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob. Agents Chemother. 54:945-949.
2. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271.
3. Beltramini AM, Mukhopadhyay CD, Pancholi V. 2009. Modulation of cell wall structure and antimicrobial susceptibility by a Staphylococcus aureus eukaryote-like serine/threonine kinase and phosphatase. Infect. Immun. 77:1406-1416.
4. Bjorkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287:1479-1482. (Pubitemid 30127140)
5. Bork P, Brown NP, Hegyi H, Schultz J. 1996. The protein phosphatase 2C (PP2C) superfamily: detection of bacterial homologues. Protein Sci. 5:1421-1425. (Pubitemid 26239449)
6. Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RS. 2001. A spectrum of changes occurs in peptidoglycan composition of glycopep-tide- intermediate clinical Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 45:280-287. (Pubitemid 32039127)
7. Bubeck Wardenburg J, Williams WA, Missiakas D. 2006. Host defenses against Staphylococcus aureus infection require recognition of bacterial lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 103:13831-13836. (Pubitemid 44413993)
8. Burnside K, et al. 2010. Regulation of hemolysin expression and virulence of Staphylococcus aureus by a serine/threonine kinase and phosphatase. PLoS One 5:e11071. doi:10.1371/journal.pone.0011071.
9. Chachaty E, Saulnier P. 2000. Isolating chromosomal DNA from bacteria, p 29-32. In Rapley R (ed), The nucleic acid protocols handbook. Humana Press, Inc, Totowa, NJ.
10. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641.
11. Cheung GY, Wang R, Khan BA, Sturdevant DE, Otto M. 2011. Role of the accessory gene regulator agr in community-associated methicillin-resistant Staphylococcus aureus pathogenesis. Infect. Immun. 79:1927-1935.
12. Clinical and Laboratory Standards Institute/NCCLS. 2009. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 8th ed. Approved standard M7-A8. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Clinical and Laboratory Standards Institute/NCCLS. 2009. Performance standards for antimicrobial susceptibility testing. Nineteenth informational supplement. M100-S19. Clinical and Laboratory Standards Institute, Wayne, PA.
14. Costello EK, et al. 2009. Bacterial community variation in human body habitats across space and time. Science 326:1694-1697.
15. Cui L, Neoh HM, Shoji M, Hiramatsu K. 2009. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53:1231-1234.
16. Cui L, Tominaga E, Neoh HM, Hiramatsu K. 2006. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin- intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 50:1079-1082. (Pubitemid 43327815)
17. Cui LZ, et al. 2010. An rpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 54:5222-5233.
18. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616-687.
19. Delcher AL, Phillippy A, Carlton J, Salzberg SL. 2002. Fast algorithms for large-scale genome alignment and comparison. Nucleic Acids Res. 30:2478-2483. (Pubitemid 34619000)
20. Diep BA, et al. 2008. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 148:249-257. (Pubitemid 351665484)
21. Diep BA, et al. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus. Lancet 367:731-739. (Pubitemid 43326291)
22. Drummelsmith J, Winstall E, Bergeron MG, Poirier GG, Ouellette M. 2007. Comparative proteomics analyses reveal a potential biomarker for the detection of vancomycin-intermediate Staphylococcus aureus strains. J. Proteome Res. 6:4690-4702.
23. Dussault AA, Pouliot M. 2006. Rapid and simple comparison of messenger RNA levels using real-time PCR. Biol. Proced. Online 8:1-10. (Pubitemid 43173726)
24. Duthie ES, Lorenz LL. 1952. Staphylococcal coagulase; mode of action and antigenicity. J. Gen. Microbiol. 6:95-107.
25. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015. (Pubitemid 30140551)
26. Entenza JM, Veloso TR, Vouillamoz J, Giddey M, Moreillon P. 2011. Failure of vancomycin continuous infusion against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 55:385-387.
27. Felden B, Vandenesch F, Bouloc P, Romby P. 2011. The Staphylococcus aureus RNome and its commitment to virulence. PLoS Pathog. 7:e1002006. doi:10.1371/journal.ppat.1002006.
28. Foucault ML, Courvalin P, Grillot-Courvalin C. 2009. Fitness cost of VanA-type vancomycin resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2354-2359.
29. Gardete S, Aires-De-Sousa M, Faustino A, Ludovice AM, de Lencastre H. 2008. Identification of the first vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolate from a hospital in Portugal. Microb. Drug Resist. 14:1-6. (Pubitemid 351441854)
30. Girish TS, Gopal B. 2010. Crystal structure of Staphylococcus aureus metallopeptidase (Sapep) reveals large domain motions between the man-ganese- bound and apo-states. J. Biol. Chem. 285:29406-29415.
31. Grice EA, Segre JA. 2011. The skin microbiome. Nat. Rev. Microbiol. 9:244-253.
32. Hageman JC, et al. 2008. Occurrence of a USA300 vancomycin-intermediate Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 62:440-442.
33. Hallin M, Friedrich AW, Struelens MJ. 2009. spa typing for epidemiological surveillance of Staphylococcus aureus. Methods Mol. Biol. 551:189-202.
34. Heikkinen O, et al. 2009. Solution structure of the parvulin-type PPIase domain of Staphylococcus aureus PrsA-implications for the catalytic mechanism of parvulins. BMC Struct. Biol. 9:17. doi:10.1186/1472-6807-9-17.
35. Highlander SK, et al. 2007. Subtle genetic changes enhance virulence of methicillin resistant and sensitive Staphylococcus aureus. BMC Microbiol. 7:99. doi:10.1186/1471-2180-7-99.
36. Hiramatsu K, et al. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136. (Pubitemid 27341646)
37. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99-139.
38. Reference deleted.
39. Howden BP, et al. 2008. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. BMC Microbiol. 8:39. doi:10.1186/1471-2180-8-39.
40. Howden BP, et al. 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin. Infect. Dis. 38:521-528. (Pubitemid 38250962)
41. Hyyrylainen HL, et al. 2010. Penicillin-binding protein folding is dependent on the PrsA peptidyl-prolyl cis-trans isomerase in Bacillus subtilis. Mol. Microbiol. 77:108-127.
42. Jansen A, et al. 2007. Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. Int. J. Med. Microbiol. 297:205-215. (Pubitemid 46830043)
43. Jousselin A, et al. 2012. The posttranslocational chaperone lipoprotein PrsA is involved in both glycopeptide and oxacillin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 56:3629-3640.
44. Kennedy AD, et al. 2010. Complete nucleotide sequence analysis of plasmids in strains of Staphylococcus aureus clone USA300 reveals a high level of identity among isolates with closely related core genome sequences. J. Clin. Microbiol. 48:4504-4511.
45. Koehl JL, et al. 2004. Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 48:3749-3757. (Pubitemid 39304599)
46. Lannergard J, Norstrom T, Hughes D. 2009. Genetic determinants of resistance to fusidic acid among clinical bacteremia isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 53:2059-2065.
47. Lessa FC, et al. 2012. Impact of USA300 methicillin-resistant Staphylococcus aureus on clinical outcomes of patients with pneumonia or central line-associated bloodstream infections. Clin. Infect. Dis. 55:232-241.
48. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
49. Lodise TP, et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
50. Lulitanond A, et al. 2009. The first vancomycin-intermediate Staphylococcus aureus strains isolated from patients in Thailand. J. Clin. Microbiol. 47:2311-2316.
51. Luo N, et al. 2005. Enhanced in vivo fitness of fluoroquinolone-resistant Campylobacter jejuni in the absence of antibiotic selection pressure. Proc. Natl. Acad. Sci. U. S. A. 102:541-546. (Pubitemid 40282701)
52. Mainiero M, et al. 2010. Differential target gene activation by the Staphylococcus aureus two-component system saeRS. J. Bacteriol. 192:613-623.
53. Marcusson LL, Frimodt-Moller N, Hughes D. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5:e1000541. doi:10.1371/journal.ppat.1000541.
54. Marty FM, et al. 2006. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 44:595-597. (Pubitemid 43224254)
55. Meehl M, Herbert S, Gotz F, Cheung A. 2007. Interaction of the GraRS two-component system with the VraFG ABC transporter to support van-comycin- intermediate resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 51:2679-2689. (Pubitemid 47206200)
56. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624.
57. Musta AC, et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640-1644.
58. Mwangi MM, et al. 2007. Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl. Acad. Sci. U. S. A. 104:9451-9456. (Pubitemid 47185800)
59. Nagaev I, Bjorkman J, Andersson DI, Hughes D. 2001. Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40:433-439. (Pubitemid 32391637)
60. Neoh HM, et al. 2008. Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous van-comycin- intermediate resistance to vancomycin-intermediate resistance. Antimicrob. Agents Chemother. 52:45-53.
61. Ohlsen K, Donat S. 2010. The impact of serine/threonine phosphorylation in Staphylococcus aureus. Int. J. Med. Microbiol. 300:137-141.
62. Ohta T, et al. 2004. Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315. DNA Res. 11:51-56. (Pubitemid 40036634)
63. Passalacqua KD, et al. 2009. Structure and complexity of a bacterial transcriptome. J. Bacteriol. 191:3203-3211.
64. Pereira SF, Goss L, Dworkin J. 2011. Eukaryote-like serine/threonine kinases and phosphatases in bacteria. Microbiol. Mol. Biol. Rev. 75:192-212.
65. Pullen KE, et al. 2004. An alternate conformation and a third metal in PstP/Ppp, the M. tuberculosis PP2C-family Ser/Thr protein phosphatase. Structure 12:1947-1954. (Pubitemid 39469392)
66. Renzoni A, et al. 2011. Whole genome sequencing and complete genetic analysis reveals novel pathways to glycopeptide resistance in Staphylococcus aureus. PLoS One 6:e21577. doi:10.1371/journal.pone.0021577.
67. Sakoulas G, et al. 2002. Accessory gene regulator (agr) locus in geographically diverse Staphylococcus aureus isolates with reduced susceptibility to vancomycin. Antimicrob. Agents Chemother. 46:1492-1502. (Pubitemid 34415333)
68. Sarvas M, Harwood CR, Bron S, van Dijl JM. 2004. Post-translocational folding of secretory proteins in Gram-positive bacteria. Biochim. Biophys. Acta 1694:311-327. (Pubitemid 39535077)
69. Satola SW, Farley MM, Anderson KF, Patel JB. 2011. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J. Clin. Microbiol. 49:177-183.
70. Scherl A, et al. 2006. Exploring glycopeptide-resistance in Staphylococcus aureus: a combined proteomics and transcriptomics approach for the identification of resistance-related markers. BMC Genomics 7:296. doi:10.1186/1471-2164-7-296.
71. Shoji M, et al. 2011. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Antimicrob. Agents Chemother. 55:3870-3881.
72. Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656. (Pubitemid 43222276)
73. Smith EJ, Visai L, Kerrigan SW, Speziale P, Foster TJ. 2011. The Sbi protein is a multifunctional immune evasion factor of Staphylococcus aureus. Infect. Immun. 79:3801-3809.
74. Sola C, et al. 2011. Heterogeneous vancomycin-intermediate susceptibility in a community-associated methicillin-resistant Staphylococcus aureus epidemic clone, in a case of infective endocarditis in Argentina. Ann. Clin. Microbiol. Antimicrob. 10:15.
75. Stoll H, Dengjel J, Nerz C, Gotz F. 2005. Staphylococcus aureus deficient in lipidation of prelipoproteins is attenuated in growth and immune activation. Infect. Immun. 73:2411-2423. (Pubitemid 40470844)
76. Tatusov RL, et al. 2003. The COG database: an updated version includes eukaryotes. BMC Bioinformatics 4:41. doi:10.1186/1471-2105-4-41.
77. Tatusov RL, Koonin EV, Lipman DJ. 1997. A genomic perspective on protein families. Science 278:631-637. (Pubitemid 27464953)
78. Twele L, et al. 2010. Methicillin-resistant Staphylococcus aureus endocarditis and de novo development of daptomycin resistance during therapy. Can. J. Infect. Dis. Med. Microbiol. 21:89-93.
79. van Hal SJ, Paterson DL, Gosbell IB. 2011. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naive patient-a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 30:603-610.
80. Vitikainen M, et al. 2004. Structure-function analysis of PrsA reveals roles for the parvulin-like and flanking N- and C-terminal domains in protein folding and secretion in Bacillus subtilis. J. Biol. Chem. 279:19302-19314. (Pubitemid 38623362)
81. Watanabe Y, Cui L, Katayama Y, Kozue K, Hiramatsu K. 2011. Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus. J. Clin. Microbiol. 49:2680-2684.
82. Yoon EJ, et al. 2010. Extended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus. Chemotherapy 56:153-157.
83. Zhang L, Jacobsson K, Strom K, Lindberg M, Frykberg L. 1999. Staphylococcus aureus expresses a cell surface protein that binds both IgG and beta2-glycoprotein I. Microbiology 145(Part 1):177-183. (Pubitemid 29043590)
84. Zhang L, Jacobsson K, Vasi J, Lindberg M, Frykberg L. 1998. A second IgG-binding protein in Staphylococcus aureus. Microbiology 144(Part 4):985-991. (Pubitemid 28187924)